Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines

W. Chung, Amy; Ghebremichael, Musie; R. Robinson, Hannah; P. Brown, Eric; Choi, Ickwon; Lane, Sophie; Dugast, Anne‐Sophie; K. Schoen, Matthew; Rolland, Morgane; J. Suscovich, Todd; E. Mahan, Alison; Liao, Larry; Streeck, Hendrik; Andrews, Charla; Rerks‐Ngarm, Supachai; Nitayaphan, Sorachai; de Souza, Mark; Kaewkungwal, Jaranit; Pitisuttithum, Punnee; P. Francis, Donald; L. Michael, Nelson; H. Kim, Jérôme; Bailey‐Kellogg, Chris; E. Ackerman, Margaret; Alter, Galit

doi:10.1126/scitranslmed.3007736

Public

Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines

Published in Science Translational Medicine • Mar 19, 2014

Authors:

Amy W. Chung

Musie Ghebremichael

Hannah R. Robinson

Abstract

The human phase 2B RV144 ALVAC-HIV vCP1521/AIDSVAX B/E vaccine trial, held in Thailand, resulted in an estimated 31.2% efficacy against HIV infection. By contrast, vaccination with VAX003 (consisting of only AIDSVAX B/E) was not protective. Because protection within RV144 was observed in the absence...

Subject

Antibody

Subclass

Vaccine trial

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!